Growth Metrics

Ligand Pharmaceuticals (LGND) Long-Term Deferred Tax (2016 - 2025)

Historic Long-Term Deferred Tax for Ligand Pharmaceuticals (LGND) over the last 14 years, with Q3 2025 value amounting to $9.5 million.

  • Ligand Pharmaceuticals' Long-Term Deferred Tax rose 1211282.05% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year increase of 1211282.05%. This contributed to the annual value of $72000.0 for FY2024, which is 6635.51% down from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Long-Term Deferred Tax stood at $9.5 million, which was up 1211282.05% from $829000.0 recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Long-Term Deferred Tax peaked at $35.7 million during Q4 2021, and registered a low of $72000.0 during Q4 2024.
  • Its 5-year average for Long-Term Deferred Tax is $14.6 million, with a median of $8.5 million in 2022.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Long-Term Deferred Tax crashed by 9908.56% in 2024, and later surged by 1211282.05% in 2025.
  • Ligand Pharmaceuticals' Long-Term Deferred Tax (Quarter) stood at $35.7 million in 2021, then plummeted by 76.13% to $8.5 million in 2022, then tumbled by 97.49% to $214000.0 in 2023, then crashed by 66.36% to $72000.0 in 2024, then skyrocketed by 13130.56% to $9.5 million in 2025.
  • Its Long-Term Deferred Tax stands at $9.5 million for Q3 2025, versus $829000.0 for Q2 2025 and $546000.0 for Q1 2025.